• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology >Percutaneous estradiol/oral micronized progesterone has less-adverse effects and different gene regulations than oral conjugated equine estrogens/medroxyprogesterone acetate in the breasts of healthy women in vivo
【24h】

Percutaneous estradiol/oral micronized progesterone has less-adverse effects and different gene regulations than oral conjugated equine estrogens/medroxyprogesterone acetate in the breasts of healthy women in vivo

机译：经皮雌二醇/口腔微粉化孕酮具有较低的效果和不同的基因规定，而不是口服共轭马雌激素/醋酸乳头酸盐的乳腺癌

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Gene expression analysis of healthy postmenopausal women in a prospective clinical study indicated that genes encoding for epithelial proliferation markers Ki-67 and progesterone receptor B mRNA are differentially expressed in women using hormone therapy (HT) with natural versus synthetic estrogens. Two 28-day cycles of daily estradiol (E2) gel 1.5 mg and oral micronized progesterone (P) 200 mg/day for the last 14 days of each cycle did not significantly increase breast epithelial proliferation (Ki-67 MIB-1 positive cells) at the cell level nor at the mRNA level (MKI-67 gene). A borderline significant beneficial reduction in anti-apoptotic protein bcl-2, favouring apoptosis, was also seen followed by a slight numeric decrease of its mRNA. By contrast, two 28-day cycles of daily oral conjugated equine estrogens (CEE) 0.625 mg and oral medroxyprogesterone acetate (MPA) 5 mg for the last 14 days of each cycle significantly increased proliferation at both the cell level and at the mRNA level, and significantly enhanced mammographic breast density, an important risk factor for breast cancer. In addition, CEE/MPA affected around 2,500 genes compared with just 600 affected by E2/P. These results suggest that HT with natural estrogens affects a much smaller number of genes and has less-adverse effects on the normal breast in vivo than conventional, synthetic therapy.
机译：健康绝经后妇女在前瞻性临床研究中的基因表达分析表明，编码上皮增殖标志物Ki-67和孕酮受体B mRNA的基因在使用激素治疗（HT）的女性中差异地表达，具有自然与合成雌激素。每天28天的日常雌二醇（E2）凝胶1.5mg和口服微粉化孕酮（P）200毫克/天每循环的最后14天没有显着增加乳房上皮增殖（Ki-67 MIB-1阳性细胞）在细胞水平或mRNA水平（MKI-67基因）。还可以看到抗凋亡蛋白BCL-2的临界显着的有益降低，并且其mRNA的略微数值降低。相比之下，每循环的后14天的每次口服共轭马雌激素（CEE）的两次28天循环（CEE）0.625mg和口服中吡炔酮（MPa）5mg在细胞水平和mRNA水平上显着增加了增殖，并且显着增强了乳房X线乳腺密度，是乳腺癌的重要危险因素。此外，CEE / MPA与2,500个基因影响，与E2 / p影响的仅600个相比。这些结果表明，具有天然雌激素的HT会影响较少数量的基因，并且对体内正常乳房具有较小的不良影响而不是常规的合成治疗。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号